Accepted Manuscript

Medicines for Pediatric Patients – Biopharmaceutical, Developmental, and Regulatory Considerations

David P. Elder, René Holm, Martin Kuentz

PII: S0022-3549(16)41944-1

DOI: 10.1016/j.xphs.2016.12.018

Reference: XPHS 595

To appear in: Journal of Pharmaceutical Sciences

Received Date: 7 April 2016

Revised Date: 24 November 2016 Accepted Date: 14 December 2016

Please cite this article as: Elder DP, Holm R, Kuentz M, Medicines for Pediatric Patients – Biopharmaceutical, Developmental, and Regulatory Considerations, *Journal of Pharmaceutical Sciences* (2017), doi: 10.1016/j.xphs.2016.12.018.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

COMMENTARY

Medicines for Pediatric Patients - Biopharmaceutical, Developmental, and **Regulatory Considerations** David P. Elder¹, René Holm², and Martin Kuentz³* ¹GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 0DP, United Kingdom. ² Drug Product Development, Jansen Research & Development, Johnson & Johnson, Turnhoutseweg 30, B-2340 Beerse, Belgium ³University of Applied Sciences and Arts Northwestern Switzerland, Institute of Pharmaceutical Technology, CH-4132 Muttenz, Switzerland. * To whom correspondence should be addressed: martin.kuentz@fhnw.ch; University of Applied Sciences and Arts Northwestern Switzerland, Institute of Pharmaceutical Technology, Gründenstr. 40, CH-4132 Muttenz, Switzerland

Download English Version:

https://daneshyari.com/en/article/8514285

Download Persian Version:

https://daneshyari.com/article/8514285

<u>Daneshyari.com</u>